Home / Psychiatry / Mood & Anxiety Disorders

Major Depressive Disorder SIGECAPS acronym: Emergency Protocols (Pharmacodynamic Summary)

Mood & Anxiety Disorders Specialty Division
â–  LECTURE OVERVIEW: Major Depressive Disorder (MDD) is a common, debilitating mood disorder diagnosed biochemically by meeting specific clinical criteria outlined in the DSM-5. â–  THE SIGECAPS CRITERIA: 1. Diagnostic threshold: Requires at least 5 of 9 symptoms present during the same 2-week period, representing a change from previous functioning, where at least one symptom must be depressed mood or anhedonia (loss of interest/pleasure). 2. The mnemonic: - S - Sleep disturbances (insomnia or hypersomnia). - I - Interest loss (profound anhedonia). - G - Guilt or feelings of worthlessness. - E - Energy depletion or fatigue. - C - Concentration difficulties or indecisiveness. - A - Appetite and weight changes (increase or decrease). - P - Psychomotor agitation or retardation. - S - Suicidal ideation or recurrent thoughts of death. â–  EMERGENCY MANAGEMENT: Acute presentation requires rapid stabilization following standard clinical guidelines. Prioritize securing the airway, maintaining hemodynamic stability, and administering targeted antidotes. â–  PHARMACODYNAMIC TARGET ENGAGEMENT: Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents. [HY-BOARD-1368]

🌟 Dynamic Clinical Key:

First-line pharmacological treatment is selective serotonin reuptake inhibitors (SSRIs; e.g., Sertraline, Escitalopram). Sexual dysfunction and weight gain are the most common reasons for treatment non-adherence and discontinuation. Do not delay emergency interventions for low-priority diagnostic tests. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.

Professional Medical Reference Application v2.5

For training, board examinations (USMLE, PLAB), and clinician benchmarking. Do not replace professional care.